Fletikumab
Monoclonal antibody
- none
- 1357158-22-5
- none
- 82WG3POL9W
- D11756
- ChEMBL3301580
Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis[2] that targets IL-20.[3]
This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
- ^ Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.
- v
- t
- e
Interleukin receptor modulators
- Agonists: Interleukin 1 (α, β)
- Mobenakin
- Pifonakin
- Antagonists: AF-12198
- Anakinra
- IL-1RA
- Isunakinra
- Antibodies: Canakinumab
- Gevokizumab
- Lutikizumab
- Decoy receptors: Rilonacept (IL-1 Trap)
- Agonists: Adargileukin alfa
- Aldesleukin
- Celmoleukin
- Denileukin diftitox
- Interleukin 2
- Pegaldesleukin
- Teceleukin
- Tucotuzumab celmoleukin
- Antibodies: Basiliximab
- Daclizumab (dacliximab)
- Inolimomab
- Agonists: Daniplestim
- Interleukin 3
- Leridistim
- Milodistim
- Muplestim
- Promegapoietin
- Agonists: Binetrakin
- Interleukin 4
- Interleukin 13
- Antagonists: Pitrakinra
- Antibodies: Dupilumab
- Pascolizumab
- Agonists: Interleukin 5
- Antagonists: YM-90709
- Antibodies: Benralizumab
- Mepolizumab
- Reslizumab
- Antisense oligonucleotides: TPI ASM8
- Agonists: Atexakin alfa
- Interleukin 6
- Antibodies: ARGX-109
- Clazakizumab
- Elsilimomab
- mAb 1339
- Olokizumab
- Sarilumab
- Siltuximab
- Sirukumab
- Tocilizumab
- Levilimab
- Agonists: Interleukin 7
- See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
- Agonists: Interleukin 9
- Antibodies: Enokizumab
- Agonists: Ilodecakin
- Interleukin 10 (CSIF)
- Agonists: Interleukin 11 (AGIF)
- Oprelvekin
- Agonists: Edodekin alfa
- Interleukin 12
- Antibodies: Briakinumab
- Ustekinumab
- Agonists: Binetrakin
- Cintredekin besudotox
- Interleukin 4
- Interleukin 13
- Antibodies: Anrukinzumab
- Lebrikizumab
- Tralokinumab
- Agonists: ALT-803
- Interleukin 15
- Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)
- Antibodies: Brodalumab
- Ixekizumab
- Perakizumab
- Remtolumab
- Secukinumab
- Vunakizumab
- Agonists: Iboctadekin
- Interleukin 18
- Interleukin 37
- Tadekinig
- Binding proteins: IL18BP
- Agonists: Interleukin 19
- Interleukin 20
- Interleukin 24
- Antibodies: Fletikumab (against IL-20)
- Agonists: Denenicokin
- Interleukin 21
- Antibodies: NNC0114-0005
- NNC0114-0006
- Agonists: Interleukin 22
- Antibodies: Fezakinumab (against IL-22)
- Agonists: Interleukin 23 (SGRF)
- Antibodies: Brazikumab
- Briakinumab
- Guselkumab
- Risankizumab
- Tildrakizumab
- Ustekinumab
- Agonists: Interleukin 27 (interleukin 30)
- Agonists: Interferon λ4 (IFN-λ4)
- Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
- Interleukin-29 (IFN-λ1)
- Agonists: Interleukin 31
- Agonists: Interleukin 33
- Agonists: Interleukin 36 (α, β, γ)
- Interleukin 38
- Antagonists: IL-36RA
| JAK |
|
|---|---|
| Others |
|
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
